Medication-assisted treatment (MAT) with buprenorphine is now widely prescribed to treat addiction to heroin and other illicit opioids. There is some evidence that illicit opioids enhance HIV-1 replication and accelerate AIDS pathogenesis, but the effect of buprenorphine is unknown.
We obtained peripheral blood mononuclear cells (PBMCs) from healthy volunteers and activated them with phytohemagglutinin and interleukin 2 for 72 hours in the presence of morphine or buprenorphine. We infected the cells with a panel of replication-competent CCR5-tropic HIV-1 reporter viruses encoding a secreted nanoluciferase gene, and measured infection by luciferase activity in the supernatants over time. We also surveyed opioid receptor expression in PBMC and vaginal leukocytes, as well as Langerhans cells derived from CD34+ hematopoietic stem cells, by qPCR.
Buprenorphine increased HIV-1 infectivity at the three MOIs tested (0.1, 0.2 and 0.5) and over all tested periods (24, 48 and 72 hours; n=3 experiments). For example, at 72 hours, HIV infection was three to six times higher in the presence of 2 nM buprenorphine (p<0.0001). Morphine also enhanced HIV-1 infection, but to a much lesser extent and only at the higher dosage. At 100 μM, morphine caused a 1.4-fold increase of infection after 72 hours (p<0.0001), whereas at 1 µM, HIV-1 infectivity remained unchanged. In none of the leukocyte types tested, we found expression of the classical opioid receptors (mu, kappa or delta), but the nociception/orphanin FQ receptor (NOP also known as OPRL1) was present in blood and vaginal lymphocytes.
Our results suggest that buprenorphine, much more than morphine, increases the susceptibility of leukocytes to HIV-1 infection in vitro. Given that leukocytes do not express the classical opioid receptors, this increase in HIV susceptibility must occur through either OPRL1 or an unknown pathway. These findings are a first step toward understanding how opioids, including those used for MAT, affect HIV infection.